Please assess the completion status of the following clinical trial:

Trial Title: Continuous Erector Spinae Plane Blocks for Rib Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* having a total of 1-6 rib fractures at least 3 cm distal to the costo-transverse joint (bilateral fractures are acceptable, but the total of the two sides combined must not exceed 6 fractures)~* regional anesthetic requested by the admitting service~* patient accepting of a perineural catheter insertion and subsequent study fluid treatment.~Exclusion Criteria:~* chronic opioid use (daily use within the 2 weeks prior to presentation and duration of use \> 4 weeks; of note, any testing for opioid use will not occur as part of the study, but may as standard of care)~* pregnancy~* incarceration~* inability to communicate with the investigators~* weight \< 45 kg or morbid obesity (body mass index \> 40 kg/m2)~* comorbidity precluding either perineural catheter insertion or subsequent ambulatory perineural local anesthetic administration (e.g., current infection at the catheter insertion site, known hepatic or renal insufficiency, immune-compromised status of any etiology)~* any patient unable to correctly perform incentive spirometry as this is the primary outcome measure~* any patient with any degree of decreased mental capacity as determined by the surgical service~* any reason an investigator believes study participation would not be in the best interest of the potential subject~* flail chest~* chest tube~* fracture of the 1st rib on either side~* any injury other than the rib fracture(s) that potentially effects inspiratory effort or volume (e.g., clavicle fracture)~* inability to contact the investigators during the perineural administration, and vice versa (e.g., lack of telephone access).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Treatment (Type: EXPERIMENTAL): This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of ropivacaine 0.3% (continuous block)
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive a single injection nerve block of ropivacaine 0.5% (20 mL) followed by an infusion/boluses of normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).